Today: 2 July 2026
Browse Category

NYSE:LLY 20 July 2025 - 28 August 2025

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com. “Making America Healthy Again” or Undermining Science?: The narrower vaccine rollout comes amid turmoil at the CDC. CDC Director Dr. Susan Monarez was fired on Aug. 27, just weeks into the job, after clashing with HHS Secretary Robert F. Kennedy Jr. over his sweeping vaccine policy changes reuters.com reuters.com. Kennedy –
28 August 2025
····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.
23 August 2025
·······
Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tariff Tsunami, Tech Tumble & Peace Talk Buzz – Global Business Roundup (Aug 19–20, 2025)

Tech Selloff and Fed Jitters: U.S. stocks swung lower on August 19 as a tech-led slide dragged the Nasdaq down about 1.5%, even as the Dow Jones Industrial Average briefly touched a record high reuters.com reuters.com. High-flying AI names like Nvidia plunged, weighing on growth stocks, amid investor anxiety over the Federal Reserve’s upcoming Jackson Hole symposium reuters.com reuters.com. “There’s an anxiety about Powell’s comments at Jackson Hole… higher interest rates have a big impact on growth stocks,” noted Ross Mayfield of Baird, reflecting fears the Fed may stay hawkish despite market bets on rate cuts reuters.com reuters.com. Futures markets were pricing in at least two quarter-point Fed rate reductions by year-end reuters.com reuters.com, even as Fed officials grapple with inflation that’s still above target. Notably, U.S. 10-year Treasury yields eased to around 4.31%, after recently hitting multi-year highs reuters.com. The U.S. dollar strengthened for a third straight session ahead of Fed Chair Jerome Powell’s August 22 speech, pushing the dollar index up to a 1½-week high reuters.com reuters.com. Peace Talk Hopes Lift Europe: In Europe, equities rallied – the STOXX 600 index rose 0.7% on Aug 19 – buoyed by renewed hopes for a Ukraine peace deal reuters.com reuters.com.
20 August 2025
········
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

For the period August 15–16, 2025, the biotech, pharma, medical, and health sectors saw a flurry of significant developments worldwide. Here is a comprehensive roundup of the top stories, categorized by theme and featuring expert insights and source links: Novo Nordisk’s blockbuster weight-loss drug Wegovy received accelerated approval from the U.S. FDA to treat metabolic dysfunction-associated steatohepatitis, a serious fatty liver disease reuters.com. This makes Wegovy the first GLP-1 class therapy cleared for MASH, an ailment affecting roughly 5% of U.S. adults reuters.com. The decision was based on part 1 of an ongoing trial showing Wegovy improved liver health and scarring in more patients than placebo reuters.com. “There really [have] not been good treatments in this space… we really need better medications that… prevent the progression of the disease,” said Jason Brett, Novo Nordisk’s U.S. medical chief reuters.com. Novo is pursuing approvals in Europe and Japan based on these interim results reuters.com, potentially strengthening its lead in metabolic diseases. Rival Eli Lilly’s tirzepatide has also shown promise in MASH in mid-stage trials reuters.com, underscoring the high-stakes race in this therapeutic area.
16 August 2025
··········
AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

AI Stock Frenzy: Big Tech Bets, Billion-Dollar Deals & Market Shifts (Aug 15–16, 2025)

Major investors are piling back into Big Tech on hopes that artificial intelligence will continue to fuel outsized growth. Fresh 13F disclosures show top hedge funds significantly boosted stakes in “Magnificent 7” AI winners during Q2. Ray Dalio’s Bridgewater more than doubled its position in Nvidia, while adding to Alphabet and Microsoft holdings reuters.com. Chase Coleman’s Tiger Global bought millions more Amazon shares and added to positions in Alphabet, Nvidia, Microsoft and Meta reuters.com. This marks a sharp reversal from earlier caution and underscores conviction that these AI leaders will drive further market gains ts2.tech ts2.tech. Indeed, a Bank of America fund manager survey just crowned “long the Magnificent 7” as the world’s most crowded trade reuters.com. These seven U.S. tech giants – from Nvidia to Tesla – have been “must-own” pillars of 2025’s rally, collectively responsible for a dominant share of the S&P 500’s year-to-date gains ts2.tech. Investors are rotating back into these momentum names after a mid-year pullback, betting that heavy AI investments will translate into sustained growth. Even as they compete, tech titans are teaming up to spread AI services. On Aug. 14, Oracle and Alphabet’s Google Cloud unveiled a landmark partnership to offer Google’s next-generation “Gemini”
16 August 2025
··········
Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Global Business Pulse: Markets Juggle Tariffs, Rate Cuts & Mega-Deals (Aug 7–8, 2025)

Equities: Global stocks seesawed amid trade and geopolitical crosswinds. On Aug 7, Wall Street’s Dow Jones and S&P 500 slipped as pharma giant Eli Lilly plunged 14% on disappointing weight-loss drug data reuters.com reuters.com. The Nasdaq Composite inched to a record high, up 0.3%, buoyed by tech gains reuters.com reuters.com. “The market rally is beginning to look a little tired… ignoring a lot of the tariff news,” observed Spartan Capital’s Peter Cardillo, as investors had bid up stocks on strong earnings despite looming U.S. import levies reuters.com. In Europe, the pan-European STOXX 600 hit a one-week peak and notched its biggest rise in over two weeks on Aug 7 reuters.com, fueled by bank stocks and hopes of a Ukraine ceasefire after news of a possible Trump-Putin peace meeting reuters.com reuters.com. By Aug 8, European shares were on track for their best week in 12 weeks, aided by a perceived dovish tilt at the Fed and easing war fears reuters.com. Asia saw an uneven rebound – Japan’s Nikkei surged 2% to a record on robust earnings and optimism that U.S. tariffs on Japanese goods would be fine-tuned reuters.com reuters.com. However, Hong Kong, Korea and Australia lagged, reflecting fragile sentiment after Wall
8 August 2025
········
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung Unveils Thinner Foldables: Samsung launched its latest foldable smartphones – the Galaxy Z Fold7 and Galaxy Z Flip7 – touting them as the thinnest, lightest iterations yet. The premium Galaxy Z Fold7 now starts at $1,999, while a new cheaper Flip7 FE comes in at $899 reuters.com. Both devices sport slimmer profiles to address past bulkiness reuters.com. Analysts say the refinements help Samsung fend off growing competition from Chinese rivals in the niche foldables market reuters.com. The company is even teasing a tri-foldable phone by year’s end reuters.com, signaling Samsung’s aggressive roadmap for foldable consumer electronics innovation. Opera’s Antitrust Complaint: In software news, Norwegian browser-maker Opera escalated its rivalry with Microsoft by filing an antitrust complaint in Brazil. Opera alleges Microsoft gives its Edge browser an unfair edge by pre-installing it as the default on Windows, hindering competition reuters.com reuters.com. “Microsoft thwarts browser competition on Windows at every turn… and then frustrates users’ ability to download and use alternative browsers,” Opera’s general counsel Aaron McParlan said in a statement reuters.com. Microsoft had no immediate comment on the complaint.
30 July 2025
·············
Blast-Off Breakthroughs: Fusion Lasers, Space Feats & Tech Triumphs in Weekend Roundup (July 19–20, 2025)

Blast-Off Breakthroughs: Fusion Lasers, Space Feats & Tech Triumphs in Weekend Roundup (July 19–20, 2025)

July 19–20, 2025 – This weekend saw a flurry of technological advancements and news spanning from orbit to the lab. In space, new satellites roared skyward and policymakers moved to save key missions. Computing hardware reached record extremes while analysts hyped the next computing revolution. A major biotech buyout validated gene-editing’s promise for disease, and the energy sector delivered breakthroughs in both renewable storage and futuristic fusion. Meanwhile, engineers pushed the frontiers of transportation with quiet supersonic flight tests, and a humanoid robot achieved a real-life “Iron Man” moment. Below is a comprehensive roundup of the biggest tech stories that defined the weekend: Roboticists hit a high-flying milestone: Researchers in Italy completed the first-ever flight of a jet-powered humanoid robot. The bipedal machine, dubbed iRonCub MK3, uses four micro turbojet engines – two strapped to its arms and two on a back-mounted pack – to achieve vertical lift. In a recent test in Genoa, iRonCub ignited its thrusters and hovered about 50 cm off the ground, while remaining stable and controlled scitechdaily.com scitechdaily.com. This makes it the world’s first humanoid robot to fly untethered. Developed by the Italian Institute of Technology, the bot is a modified version of their child-sized
20 July 2025
·····
1 … 11 12 13

Stock Market Today

  • COLD, CBAN, DDI land on Zacks Strong Sell list after estimate cuts
    July 2, 2026, 5:42 AM EDT. Americold Realty Trust (COLD), Colony Bankcorp (CBAN) and DoubleDown Interactive (DDI) moved to the Zacks Rank #5 (Strong Sell) list on July 2nd. Earnings estimates dropped for all three over the last 60 days, with COLD down 5.9%, CBAN off 6.4%, and DDI cut 5.8%. The Zacks Consensus Estimate combines analyst forecasts and revisions. Zacks also pointed to a satellite communications stock they think could double next year on expected 2025 revenue growth. Full reports and future picks are available from Zacks Investment Research.
Go toTop